Cisplatin-induced haemolytic uraemic syndrome associated with a novel intronic mutation of CD46 treated with eculizumab

Rodney D. Gilbert1,2, Louise K. Stanley3, Darren J. Fowler4, Elizabeth M. Angus5, Steven A. Hardy3 and Timothy H. Goodship6

1Regional Paediatric Nephro-Urology Unit, University Hospital Southampton NHS Foundation Trust, Southampton, UK, 2School of Medicine, University of Southampton, Southampton, UK, 3Northern Molecular Genetics Service, International Centre for Life, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK, 4Department of Histopathology, University Hospital Southampton NHS Foundation Trust, Southampton, UK, 5Biomedical Imaging Unit, University Hospital Southampton NHS Foundation Trust, Southampton, UK and 6Institute of Genetic Medicine, Newcastle University, International Centre for Life, Newcastle upon Tyne, UK

Correspondence and offprint requests to: Rodney D. Gilbert; E-mail: rodney.gilbert@uhs.nhs.uk, rodneygilbert@supanet.com

Background

Haemolytic uraemic syndrome (HUS) is most frequently caused by infection with Shiga toxin-producing strains of Escherichia coli or Shigella dysenteriae type 1. Other causes include inherited and acquired abnormalities affecting the alternative pathway of complement, other infections and certain drugs [1], including cisplatin [2] and carboplatin [3]. Recently eculizumab, a humanized monoclonal antibody directed against C5 that prevents the activation of the terminal complement pathway, has been shown to be an effective treatment for patients with atypical HUS (aHUS) [4].

Thrombotic microangiopathy has long been recognized as a complication of disseminated cancer [5] and cisplatin therapy [6]. There are two patterns of presentation of cisplatin-associated HUS. Some patients present acutely, days after receiving the last dose of chemotherapy. Others present more insidiously with a latent period of up to 7 months [2]. The acute form has a high mortality rate, although successful treatment with plasma exchange has been described [2, 7, 8].

Case report

A previously well 27-month-old boy with no family history of kidney disease presented with a cervical mass unresponsive to antibiotics. The plasma lactate dehydrogenase (LDH) was elevated at 1600 iu/L (normal 266–500). Biopsy of the mass confirmed neuroblastoma with MYCN gene amplification. Bone marrow examination and metaiodobenzylguanidine (MIBG) scan showed no evidence of distant metastases. Pre-treatment, the plasma creatinine concentration was 21 μmol/L, and the glomerular filtration rate (GFR; measured by plasma disappearance of Technetium (Tc)-99m labelled Diethylene Triamine Pentaacetic Acid (DTPA) was 107 mL/min/1.73 m2 body surface area. Therapy was started with a combination of vincristine, etoposide, carboplatin, cisplatin and cyclophosphamide.

On Day 45 of treatment (35 days after the first cisplatin dose, 15 days after the second), the GFR had fallen to 60 mL/min/1.73 m2. This was presumed to be due to acute cisplatin nephrotoxicity. Two days later, the patient became fluid overloaded and hypertensive. He was profoundly pancytopenic, which was attributed to chemotherapy-induced myelosuppression. The hypertension became increasingly severe (maximum value recorded 160 mmHg systolic) and he required five agents to control the blood pressure.

He required seven infusions of platelets and four of red blood cells between Days 50 and 59, suggesting that the pancytopenia was not solely due to myelosuppression and the plasma creatinine concentration rose from 39 to 140 μmol/L. A diagnosis of HUS was considered. A blood film confirmed the presence of schistocytes, the LDH had risen to 2438 iu/L and the plasma haptoglobin concentration was <0.06 g/L (normal 0.5–2.0 g/L). Serum
complement C3 (1.06 g/L) and C4 (0.20 g/L) concentrations were normal. Renal biopsy was considered unsafe at this time, but the results above were considered compatible with a diagnosis of HUS, likely due to cisplatin. Stool and blood cultures were negative, as were serological tests for HIV1 & 2. ADAMTS13 (von Willebrand factor-cleaving protease) levels were 80% of control values.

Despite the dearth of information concerning the pathogenesis of cisplatin/carboplatin-associated chemotherapy, we opted for therapy with eculizumab partly because it was felt that his severe hypertension, profound thrombocytopaenia and small size made plasma exchange hazardous. He received the first dose of 600 mg the following day when his plasma creatinine was 155 μmol/L. The next day the plasma creatinine peaked at 160 μmol/L and it steadily decreased thereafter (Figure 1). He also required progressively less blood product support. After a further dose of 300 mg a week later, he was maintained on fortnightly doses of 300 mg according to the manufacturer’s dosing guidelines. Five weeks after administration of the first dose of eculizumab, the plasma creatinine concentration had reduced to 34 μmol/L, the plasma LDH was 532 iu/L and the GFR was 67 mL/min/1.73 m². A decision was made to avoid further exposure to platinum-containing agents, and therapy was changed to a combination of vincristine, topotecan and doxorubicin. There was little further change in tumour size and, 126 days after starting chemotherapy, the tumour was surgically removed with clear excision margins and eculizumab was discontinued. At this time, the platelet count was 181 × 10⁹/L and the plasma creatinine concentration was 34 μmol/L.

The platelet count fell to 138 four weeks after the last eculizumab dose and remained in the range of 98–160 × 10⁹/L for the next 2 months. The plasma creatinine remained stable for 6 weeks, and then rose to 44 μmol/L. Two months after discontinuing the eculizumab, the plasma LDH had risen to 807 iu/L. The serum haptoglobin was low at 0.4 g/L and rose to 0.96 g/L a week after the first dose. After 7 months of eculizumab therapy, the patient had normal haemoglobin (122 g/L), normal platelets (248 × 10⁹/L) and a plasma creatinine concentration of 32 μmol/L. The GFR had risen to 71 mL/min/1.73 m². The plasma concentration of sC5b-9 remained elevated at 133 ng/mL, casting doubt on the suitability of this assay for assessing activity and response to treatment.

DNA extracted from a buccal smear at the time of diagnosis of HUS was amplified by PCR for all coding exons ± 10 bases of the CFH (factor H), CFI (factor I), C3 (complement component 3), CFB (factor B) and CD46 (membrane cofactor protein, MCP) genes. Amplified products were subjected to bi-directional Sanger sequencing (ABI), as previously described [9]. CD46 expression on cell surfaces was assessed on peripheral blood neutrophils after recovery from myelosuppression by flow cytometry using CD46 fluorescein isothiocyanate-conjugated antibody (BD Pharmingen, 555949).

An intronic sequence variant (c.1027+5G>T) was identified in CD46. This variant had not been previously reported nor was it detected in DNA from 188 normal control subjects. In silico splicing prediction analysis undertaken using Alamut (Interactive Bioscience Software, Seine Biopolis, 70 route de Lyons-la-Forêt, 76 000 Rouen, France; http://www.interactive-biosoftware.com) suggests that this variant may cause aberrant splicing. Flow cytometry analysis showed reduced CD46 expression on neutrophils compatible with haploinsufficiency. After discussion with the parents, a decision was made not to test other family members, because the result was felt to be of limited clinical utility, outweighed by potential anxiety induced in a carrier.

**Discussion**

There is evidence that cisplatin causes widespread endothelial damage [10]. Within the glomerulus, endothelial cells, glomerular basement membrane and podocytes all show ultrastructural evidence of damage after cisplatin exposure [11]. Opsonization of damaged or apoptotic cells with C3b plays an important role in the efficient removal of such cells by phagocytes [12], and there is evidence of complement activation in cisplatin-induced AKI. On host cell surfaces, deposited C3b is usually rapidly inactivated by several regulatory proteins including CD46 (MCP) and factor H, both of which act as cofactors for factor I. Deficiency or reduced activity of these complement regulatory proteins would potentially lead to amplification of the endothelial cell damage induced by cisplatin. This in turn would potentiate and maintain the thrombotic microangiopathy. aHUS is most frequently associated with impaired regulation of the alternate pathway of complement regulation on the surface of host cells with normal regulation in the fluid phase, and plasma C3 levels are therefore frequently normal [13].

Because endothelial damage is associated with complement activation [14] and C5 plays a pivotal role in the development of aHUS [15], it seemed appropriate to initiate treatment with eculizumab. The clinical condition of our patient improved rapidly after starting eculizumab. The finding of a novel mutation causing decreased expression of CD46 suggests that dysregulated complement activation played an important role in pathogenesis. The response to eculizumab, deterioration on withdrawal of eculizumab and improvement after restarting treatment all support this hypothesis. Our patient is the first to have genetic investigation of the factors...
Fig. 1. Graph summarizing key laboratory results. Thin arrows indicate doses of cisplatin; bold arrows indicate doses of eculizumab.
involved in the regulation of the alternative pathway of complement regulation and the first to be treated with eculizumab. The possibility that dysregulated complement activation underlies the thrombotic microangiopathy in other patients with cisplatin-induced HUS should be considered, and testing for abnormalities of complement regulation should be performed in future patients. Eculizumab therapy may be useful in other patients with cisplatin-induced HUS. The optimal duration of eculizumab therapy remains unclear; 4 months of therapy was clearly inadequate in our patient but we hope to be able to withdraw treatment in the future.

Acknowledgements. We thank Lisa Strain of the Northern Molecu- lar Genetics Laboratory, Newcastle-upon-Tyne and Deborah Dockey of the Department of Immunology, Newcastle-upon-Tyne for laboratory analysis and advice. Dr Shuman Haq of the Regional Paediatric Nephro-Urology Unit and Dr Juliet Gray of the Paediatric Oncology Unit, University Hospital Southampton for clinical input.

Conflict of interest statement. R.D.G. and T.H.G. have received fees for speaking at events sponsored by Alexion. R.D.G. received a travel grant to attend the ERA-EDTA conference in Paris in 2012. This manuscript has not been published in any format elsewhere.

References

1. Besbas N, Karpman D, Landau D et al. A classification of hemolytic uraemic syndrome and thrombotic thrombocytopenia and related disorders. Kidney Int 2006; 70: 423–431

2. Canpolat C, Pearson P, Jaffe N. Cisplatin-associated haemolytic uraemic syndrome. Cancer 1994; 74: 3059–3062

3. Walker RW, Rosenblum MK, Kempin SJ et al. Carboplatin-associated thrombotic microangiopathic haemolytic anaemia. Cancer 1989; 64: 1017–1020

4. Loirat C, Frémeaux-Bacchi V. Atypical haemolytic uraemic syn- drome. Orphanet J Rare Dis 2011; 6: 60

5. Gordon LI, Kwaan HC. Cancer and drug-associated thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome. Semin Hematol 1997; 34: 140–147

6. Jackson AM, Rose BD, Groff LG et al. Thrombotic angiopathy and renal failure associated with antineoplastic chemotherapy. Ann Int Med 1994; 101: 41–44

7. Mathur RV, Kumar S, Aparicio S et al. Haemolytic uraemic syn- drome following chemotherapy for an unusual germ-cell tumour. Nephrol Dial Transplant 1998; 14: 1786–1788

8. Thurner D, Kletzmayr J, Formanek M et al. Chemotherapy-related haemolytic-uremic syndrome following treatment of a carcinoma of the nasopharynx. Oncology 2001; 61: 143–146

9. Moore I, Strain L, Pappworth I et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4 and with mutations in CFH, CFI, CD46, and C3 in patients with atypical haemolytic uraemic syndrome. Blood 2010; 115: 379–387

10. Dieckmann K-P, Struss WJ, Budde U. Evidence for acute vas- cular toxicity of cisplatin-based chemotherapy in patients with germ cell tumour. Anticancer Res 2011; 31: 4501–4506

11. Kohn S, Fradis M, Ben-David J et al. Nephrotoxicity of comb- ined treatment with cisplatin and gentamicin in the guinea- pig: glomerular injury findings. Ultrastruct Pathol 2002; 26: 371–382
12. Mevorach D, Mascarenhas JO, Gershov D et al. Complement-dependent clearance of apoptotic cells by human macrophages. *J Exp Med* 1998; 188: 2313–2320

13. Frémeaux-Bacchi V, Fakhouri F, Garnier A et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. *Clin J Am Soc Nephrol* 2013; 8: 554–562

14. Banz Y, Rieben R. Role of complement and perspectives for intervention in ischaemia-reperfusion damage. *Ann Med* 2012; 44: 205–217

15. De Jorge EG, Macor P, Paixão-Cavalcante D et al. The development of atypical haemolytic uremic syndrome depends on complement C5. *J Am Soc Nephrol* 2011; 22: 137–145

Received for publication: 30.4.13; Accepted in revised form: 23.5.13